143 related articles for article (PubMed ID: 21830945)
21. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting.
Cohen SY; Dubois L; Tadayoni R; Fajnkuchen F; Nghiem-Buffet S; Delahaye-Mazza C; Guiberteau B; Quentel G
Am J Ophthalmol; 2009 Sep; 148(3):409-13. PubMed ID: 19477713
[TBL] [Abstract][Full Text] [Related]
22. Antiangiogenic approaches to age-related macular degeneration today.
Bressler NM
Ophthalmology; 2009 Oct; 116(10 Suppl):S15-23. PubMed ID: 19800535
[TBL] [Abstract][Full Text] [Related]
23. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration.
Rosenfeld PJ; Heier JS; Hantsbarger G; Shams N
Ophthalmology; 2006 Apr; 113(4):623.e1. PubMed ID: 16581423
[TBL] [Abstract][Full Text] [Related]
24. Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age-related macular degeneration.
Cunningham ET; Feiner L; Chung C; Tuomi L; Ehrlich JS
Ophthalmology; 2011 Dec; 118(12):2447-52. PubMed ID: 21872935
[TBL] [Abstract][Full Text] [Related]
25. [The results of wet AMD treatment by intravitreal injections--preliminary report].
Okruszko A; Borucka AI; Ulińska M; Szaflik J
Klin Oczna; 2007; 109(10-12):389-93. PubMed ID: 18488380
[TBL] [Abstract][Full Text] [Related]
26. Anti vascular endothelial growth factor sequential therapy for neovascular age-related macular degeneration: is this the new deal?
Neri P; Mariotti C; Arapi I; Bambini E; Giovannini A
Curr Med Res Opin; 2012 Mar; 28(3):395-400. PubMed ID: 22283373
[TBL] [Abstract][Full Text] [Related]
27. Retinal pigment epithelial tear after intravitreal ranibizumab.
Bakri SJ; Kitzmann AS
Am J Ophthalmol; 2007 Mar; 143(3):505-7. PubMed ID: 17317396
[TBL] [Abstract][Full Text] [Related]
28. Angiographic regression patterns after intravitreal ranibizumab injections for neovascular age-related macular degeneration.
Tran TH; Querques G; Forzy G; Souied EH
Ophthalmic Surg Lasers Imaging; 2011; 42(6):498-508. PubMed ID: 21830744
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits.
Gaudreault J; Fei D; Beyer JC; Ryan A; Rangell L; Shiu V; Damico LA
Retina; 2007; 27(9):1260-6. PubMed ID: 18046235
[TBL] [Abstract][Full Text] [Related]
30. Influence of non-toxic doses of bevacizumab and ranibizumab on endothelial functions and inhibition of angiogenesis.
Barzelay A; Lowenstein A; George J; Barak A
Curr Eye Res; 2010 Sep; 35(9):835-41. PubMed ID: 20795866
[TBL] [Abstract][Full Text] [Related]
31. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration.
Kaiser PK; Blodi BA; Shapiro H; Acharya NR;
Ophthalmology; 2007 Oct; 114(10):1868-75. PubMed ID: 17628683
[TBL] [Abstract][Full Text] [Related]
32. [Morphometric analysis of corneal endothelium after intravitreal ranibizumab (Lucentis) in age-related macular degeneration treatment].
Benítez-Herreros J; Pérez-Rico C; Teus MA; Gómez-San Gil Y; Castro-Rebollo M
Arch Soc Esp Oftalmol; 2010 Oct; 85(10):329-32. PubMed ID: 21168057
[TBL] [Abstract][Full Text] [Related]
33. A 1-year retrospective review of ranibizumab for naive nonsubfoveal choroidal neovascularization secondary to age-related macular degeneration.
Arias L; Ruiz-Moreno JM; Gómez-Ulla F; Fernández M; Montero J
Retina; 2009; 29(10):1444-9. PubMed ID: 19730163
[TBL] [Abstract][Full Text] [Related]
34. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration.
Boyer DS; Antoszyk AN; Awh CC; Bhisitkul RB; Shapiro H; Acharya NR;
Ophthalmology; 2007 Feb; 114(2):246-52. PubMed ID: 17270674
[TBL] [Abstract][Full Text] [Related]
35. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2.
Abraham P; Yue H; Wilson L
Am J Ophthalmol; 2010 Sep; 150(3):315-324.e1. PubMed ID: 20598667
[TBL] [Abstract][Full Text] [Related]
36. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration.
Brown MM; Brown GC; Brown HC; Peet J
Ophthalmology; 2008 Jun; 115(6):1039-1045.e5. PubMed ID: 17976724
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration.
Dadgostar H; Ventura AA; Chung JY; Sharma S; Kaiser PK
Ophthalmology; 2009 Sep; 116(9):1740-7. PubMed ID: 19643484
[TBL] [Abstract][Full Text] [Related]
38. Bevacizumab and ranibizumab on microvascular endothelial cells: A comparative study.
Costa R; Carneiro A; Rocha A; Pirraco A; Falcão M; Vasques L; Soares R
J Cell Biochem; 2009 Dec; 108(6):1410-7. PubMed ID: 19859900
[TBL] [Abstract][Full Text] [Related]
39. Intravitreal injection of anti-VEGF and diagnosis of primary intraocular central nervous system lymphoma.
Gambrelle J; Missotten G; Delhoum S; Desjardins L
J Fr Ophtalmol; 2013 May; 36(5):431-4. PubMed ID: 23306179
[TBL] [Abstract][Full Text] [Related]
40. Compatibility of recombinant tissue plasminogen activator (rtPA) and aflibercept or ranibizumab coapplied for neovascular age-related macular degeneration with submacular haemorrhage.
Klettner A; Grotelüschen S; Treumer F; Roider J; Hillenkamp J
Br J Ophthalmol; 2015 Jun; 99(6):864-9. PubMed ID: 25740806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
